ArticleOncology letters2018
Downregulation of ERBB3 decreases the proliferation, migration and invasion of cervical cancer cells though the interaction with MTK-1.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 13 citations in OpenAlex.
- MAP3K4 kinase action and dual role in cancer.Discover oncology · 2024Review
- Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape.Pharmaceuticals (Basel, Switzerland) · 2023Review
- ERBB3 methylation and immune infiltration in tumor microenvironment of cervical cancer.Scientific reports · 2022Article
- UHRF2 promotes Hepatocellular Carcinoma Progression by Upregulating ErbB3/Ras/Raf Signaling Pathway.International journal of medical sciences · 2021Observational
- Comparison of Cancer Cell Elasticity by Cell Type.Journal of Cancer · 2020Article
- Upregulation of lncRNA GATA6-AS suppresses the migration and invasion of cervical squamous cell carcinoma by downregulating MTK-1.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer is a common malignancy in females. Diagnosis and treatment of cervical cancer remains a challenge due to difficulties in the presence of tumor metastasis. Increased expression level of Erb-b2 receptor tyrosine kinase 3 (ERBB3) has previously been demonstrated to be associated with the occurrence of cervical cancer; however, the functionality of ERBB3 in the development of cervical cancer remains incompletely understood. In the present study, the expression level of ERBB3 in patients with cervical squamous cell carcinoma and cervical adenocarcinoma was detected by reverse transcription quantitative polymerase chain reaction. The effects of ERBB3 small interfering RNA silencing on cell proliferation, migration and invasion were explored, and the interaction between ERBB3 and mitogen-activated protein kinase kinase kinase 4 (MTK-1) was also investigated. It was identified that the downregulation of ERBB3 significantly decreased the proliferative, migratory and invasive abilities of cervical cancer cells. In addition, the expression level of MTK-1 was also significantly decreased following MTK-1 siRNA silencing. Therefore, we hypothesize that the downregulation of ERBB3 may decrease the proliferative, migratory and invasive abilities of cervical cancer cells by inhibiting the expression of MTK-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.